Program Agenda

7:00 am Registration and Continental Breakfast

7:20 am Welcome and Introduction of Opening Keynote, John A. Boockvar, MD

7:35 am Opening Keynote Address, Michael A. Vogelbaum MD, PhD, FAANS, FACS
First-in-Human Clinical Trial of the Cleveland Multiport Catheter for Delivery of Therapeutics to the Brain

Morning Scientific Session I

Update on Immunomodulatory Therapies for GBM
Session Moderator: Michael Schulder, MD, FAANS

8:00 am Prophage Platforms for Malignant GliomaJennifer S. Buell, PhD

8:20 am Immunotherapy in Glioblastoma Multiforme: Scientific Rationale for Investigation of SL-701Jonathan D. Schwartz, MD

8:40 am Rindopepimut; an Anti-EGRFvIII Vaccine for GBMThomas Davis, MD

9:00 am Special Guest, ​Anthony Scaramucci
My Experience Navigating Financial Markets, Biotech, Foundation and Philanthropy

9:20 am Networking Coffee Break, Weisner Conference Center

Morning Scientific Session II

New Delivery Modalities
Session Moderator:​ Alexis Demopoulos, MD

9:55 am Introduction of Session, Michael Klipper

10:00 am The VeraVec Endothelial Cell Platform for Cell Based Delivery, C. Geoffrey Davis, PhD

10:20 am Precisa Platform for Brain Tumor Therapies, Brian A. Leuthner

10:40 am Novel Approaches using Cesium-131 Brachytherapy in the Treatment of Intra-Cranial MalignanciesWilliam A. Cavanagh

Morning Scientific Session III

Novel Applications and Treatment for Malignant Glioma
Session Moderator:Marc Symons, PhD

11:05 am Personalized Cancer Immunotherapy, Ugur Sahin, MD

11:20 am Attacking Malignant Glioma Using a Non-lytic Virus, Jamey R. Skillings, MD

11:35 am A Peptide-drug Conjugation Strategy to Penetrate the BBB​Jean Lachowicz, PhD

11:50 am Morning Keynote Address​Donald M. O’Rourke, MD
CAR-T Approaches to GBM

12:10 pm Lunch and Networking, Weisner Conference Center

1:10 pm Introduction of Panel Michael J. Dowling

1:15 pm ​Panel Discussion: How to get your research or company noticed. Lessons from the investment expertsVC Round Table Panelists Q&A: Franklin M. Berger, CFA; Matthew Cohen, PhD; Adam Goulburn PhD; Bruce Leuchter, MD; Tommy Nguyen, MD, PhD

Afternoon Scientific Session I

Session Moderator:Rosamaria Ruggieri, PhD

1:50 pm Introduction of Keynote, Kevin J. Tracey, MD

2:00 pm Afternoon Keynote Address, Robert B. Darnell, MD, PhD
The New York Genome Center Project and the Treatment of GBM

2:20 pm Featured Company Spotlight: SetPoint Medical, Anthony Arnold
Vagal Nerve Stimulation to Alter CNS Immunology

​Afternoon Scientific Session II

Session Moderator:Jonathan P.S. Knisely, MD

2:45 pm Afternoon Keynote Address: PD-1, CTLA-4 Targets in GBM, Michael Lim, MD

3:10 pm Using Patient Derived Glioma Stem Cells for Personalized GBM Therapies, Matthew De Silva

3:40 pm Benzopyrans. Novel Therapeutics for Neurogenesis and the Treatment of Neural CancersGraham Kelly, PhD

4:00 pm Harnessing Recombinant Human MFG-E8 and Its Role after Radiation TherapyWeng-Lang Yang, PhD

4:20 pm First-in-class Small Molecule ONC201 is Effective Against Newly Diagnosed and Recurrent GBM In Preclinical ModelsJoshua E. Allen, PhD

4:40 pm Closing Remarks

5:00 pm Wine and Cheese Networking Reception at Orsay Restaurant